169 related articles for article (PubMed ID: 10528788)
21. [In vitro kinetics of the activity of fusidic acid and fluoroquinolones combinations against staphylococci according to methicillin-resistance phenotype. Implications for the treatment of osteoarticular infections].
Reynaud AE; Espaze EP; Coste-Burel M; Richet H
Pathol Biol (Paris); 1992 May; 40(5):466-70. PubMed ID: 1495828
[TBL] [Abstract][Full Text] [Related]
22. Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates.
Yu F; Liu Y; Lu C; Lv J; Qi X; Ding Y; Li D; Huang X; Hu L; Wang L
BMC Microbiol; 2015 Oct; 15():210. PubMed ID: 26463589
[TBL] [Abstract][Full Text] [Related]
23. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK.
Ravenscroft JC; Layton A; Barnham M
Clin Exp Dermatol; 2000 Jun; 25(4):327-30. PubMed ID: 10971497
[TBL] [Abstract][Full Text] [Related]
24. Fusidic acid as a potential antistaphylococcal agent.
Nicholson J; Chew T; Smith S
N Z Med J; 1999 Jul; 112(1091):261-2. PubMed ID: 10448991
[No Abstract] [Full Text] [Related]
25. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
[TBL] [Abstract][Full Text] [Related]
26. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.
Gemmell CG; Edwards DI; Fraise AP; Gould FK; Ridgway GL; Warren RE;
J Antimicrob Chemother; 2006 Apr; 57(4):589-608. PubMed ID: 16507559
[TBL] [Abstract][Full Text] [Related]
27. Next-Generation Sequence Analysis Reveals Transfer of Methicillin Resistance to a Methicillin-Susceptible Staphylococcus aureus Strain That Subsequently Caused a Methicillin-Resistant Staphylococcus aureus Outbreak: a Descriptive Study.
Weterings V; Bosch T; Witteveen S; Landman F; Schouls L; Kluytmans J
J Clin Microbiol; 2017 Sep; 55(9):2808-2816. PubMed ID: 28679522
[TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of fusidic acid against methicillin-resistant Staphylococcus aureus.
Erdenizmenli M; Yapar N; Sengönül A; Yüce A; Cakir N; Yulug N
J Chemother; 2004 Jun; 16(3):310-1. PubMed ID: 15330332
[No Abstract] [Full Text] [Related]
29. Activity of eleven antimicrobial agents against methicillin-, methicillin- and rifampin-resistant Staphylococcus aureus.
Chokkavelu V; Chandrasekar P; Rolston K; LeFrock JL; Schell RF
Chemotherapy; 1984; 30(2):97-101. PubMed ID: 6559665
[TBL] [Abstract][Full Text] [Related]
30. The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR).
Gottlieb T; Mitchell D
J Antimicrob Chemother; 1998 Jul; 42(1):67-73. PubMed ID: 9700530
[TBL] [Abstract][Full Text] [Related]
31. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
32. Fusidic acid: new opportunities with an old antibiotic.
Anderson JD
Can Med Assoc J; 1980 Apr; 122(7):765-9. PubMed ID: 6988070
[TBL] [Abstract][Full Text] [Related]
33. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing.
Mason BW; Howard AJ; Magee JT
J Antimicrob Chemother; 2003 Apr; 51(4):1033-6. PubMed ID: 12654748
[TBL] [Abstract][Full Text] [Related]
34. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections.
Hurdle JG; O'Neill AJ; Chopra I
J Antimicrob Chemother; 2004 Aug; 54(2):549-52. PubMed ID: 15243028
[TBL] [Abstract][Full Text] [Related]
35. Efforts to support the development of fusidic acid in the United States.
Fernandes P; Pereira D
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S542-6. PubMed ID: 21546632
[TBL] [Abstract][Full Text] [Related]
36. A Norwegian nosocomial outbreak of methicillin-resistant Staphylococcus aureus resistant to fusidic acid and susceptible to other antistaphylococcal agents.
Andersen BM; Bergh K; Steinbakk M; Syversen G; Magnaes B; Dalen H; Bruun JN
J Hosp Infect; 1999 Feb; 41(2):123-32. PubMed ID: 10063474
[TBL] [Abstract][Full Text] [Related]
37. Introduction: fusidic acid enters the United States.
Moellering RC; Corey GR; Grayson ML
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S467-8. PubMed ID: 21546622
[No Abstract] [Full Text] [Related]
38. Resistance to fusidic acid.
Turnidge J; Collignon P
Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S35-44. PubMed ID: 10528785
[TBL] [Abstract][Full Text] [Related]
39. Fusidic acid resistance in Staphylococcus aureus isolates.
Brown EM; Thomas P
Lancet; 2002 Mar; 359(9308):803. PubMed ID: 11888633
[No Abstract] [Full Text] [Related]
40. Clinical experiences with fusidic acid in cystic fibrosis patients.
Jensen T; Lanng S; Faber M; Rosdahl VT; Høiby N; Koch C
J Antimicrob Chemother; 1990 Feb; 25 Suppl B():45-52. PubMed ID: 2312445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
